Anirban Maitra Congratulates Van Morris on New Cancer Cell Study on Triple Therapy in mCRC
Anirban Maitra, Professor at MD Anderson Cancer Center, shared on X about a recent paper by Van Morris et al. published on Cancer Cell:
“Congratulations to Van Morris, MD Anderson Cancer Center for his new Cancer Cell study.
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic Colorectal Cancer
Thanks for the opportunity to contribute to the study!
Our main contribution was related to assessment of extracellular vesicle RNA (evRNA) in blood which provides surprisingly promising signatures of resistance and response to the triple therapy, + in depth information on tumor intrinsic pathways not gleaned by ctDNA.”
Title: Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer
Authors: Van K. Morris, Christine M. Parseghian, Vahid Bahrambeigi, Nourhan Abdelfattah, Lianchun Xiao, Anjali Agrawal, Kangyu Lin, Kanwal P.S. Raghav, Robert A. Wolff, Arvind Dasari, Ryan W. Huey, Bryan K. Kee, Michael J. Overman, Jason A. Willis, Phat H. Le, Michelle Escano, Yunyu C. Baig, Kelsey Pan, David Menter, Alda L. Tam, Wai C. Foo, Li Shen, Hey Min Lee, Thomas D. Gallup, Cori Margain, Dave Gallup, Kimal I. Rajapakshe, Paola A. Guerrero, Jing Wang, Ryan B. Corcoran, Anirban Maitra, Kyuson Yun, Scott Kopetz.
More posts featuring Anirban Maitra.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023